Key Points
- Insider Campbell Rogers sold 64,533 shares on April 1 at an average price of $24.64 for a total of $1.59M, reducing his stake by 44.34% to 81,002 shares; the sale was executed under a pre-arranged Rule 10b5-1 trading plan.
- Heartflow stock trades near the mid-$20s (opened $24.83), with a 52-week range of $20.13–$41.22, a market cap of about $2.13B and a negative P/E of -12.48, reflecting ongoing unprofitability.
- Analysts hold a consensus of “Moderate Buy” with an average price target of $37.67, though recent notes show mixed adjustments (some price targets raised to the low $40s and others cut to $35).
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) insider Campbell Rogers sold 64,533 shares of the firm's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $24.64, for a total transaction of $1,590,093.12. Following the completion of the transaction, the insider directly owned 81,002 shares of the company's stock, valued at approximately $1,995,889.28. The trade was a 44.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Campbell Rogers also recently made the following trade(s):
- On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The stock was sold at an average price of $25.69, for a total transaction of $1,657,852.77.
- On Thursday, February 12th, Campbell Rogers sold 65,153 shares of Heartflow stock. The stock was sold at an average price of $24.49, for a total value of $1,595,596.97.
Heartflow Price Performance
Heartflow stock opened at $24.83 on Friday. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $41.22. The business has a 50-day simple moving average of $25.12 and a 200 day simple moving average of $29.90. The stock has a market cap of $2.13 billion and a price-to-earnings ratio of -12.48.
Institutional Trading of Heartflow
Several hedge funds have recently added to or reduced their stakes in HTFL. Caitong International Asset Management Co. Ltd bought a new position in shares of Heartflow during the fourth quarter valued at about $27,000. TFC Financial Management Inc. bought a new position in Heartflow during the 3rd quarter worth approximately $40,000. Russell Investments Group Ltd. purchased a new position in Heartflow in the 4th quarter worth approximately $45,000. Legal & General Group Plc bought a new stake in Heartflow in the third quarter valued at approximately $59,000. Finally, Strs Ohio purchased a new stake in shares of Heartflow during the fourth quarter valued at approximately $99,000.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Canaccord Genuity Group boosted their price objective on Heartflow from $40.00 to $43.00 and gave the stock a "buy" rating in a report on Thursday, March 19th. Wells Fargo & Company dropped their target price on shares of Heartflow from $38.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, March 19th. Weiss Ratings reissued a "sell (d)" rating on shares of Heartflow in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Heartflow from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, March 19th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.67.
Check Out Our Latest Analysis on Heartflow
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
